589 RUBY trial post hoc analysis of number needed to treat and incremental costs per outcome of dostarlimab + carboplatin-paclitaxel (CP) vs placebo + CP for primary advanced/recurrent endometrial cancer

• Llenalia Garcia-Fernandez,
• Jean Hurteau,
• Lydia Lee,
• Solomon J Lubinga,
• Tilman Payer,
• Meghann Gregg,
• Odette Allonby

Affiliations

Llenalia Garcia-Fernandez

2Parexel, Madrid, Spain

Jean Hurteau

1GSK, Collegeville, PA, USA

Lydia Lee

1GSK, Collegeville, PA, USA

Solomon J Lubinga

4GSK, Collegeville, PA, USA

Tilman Payer

2Parexel, Madrid, Spain

Meghann Gregg

3Parexel, Durham, NC, USA

Odette Allonby

5GSK, Mississauga, ON, Canada